Hikma’s Injectables Business Expands As It Completes Custopharm Acquisition
Completion Of $425m Deal Comes Shortly After FTC Approved The Transaction
Executive Summary
Hikma has completed its acquisition of Custopharm, expanding its US injectables business as the company continues to look for more deals.
You may also be interested in...
Hikma Expectations Stabilize – But Generics Still Set To Take A Hit
After multiple cuts to its Generics guidance earlier this year, Hikma has reiterated its expectations for the company’s full-year results, citing momentum for the firm’s Injectables and Branded segments as well as promising that growth is on the horizon for Generics in 2023.
Hikma Will Push Harder To Make M&A Happen
Following a challenging first half for Hikma, executive chairman and CEO Said Darwazah talks to Generics Bulletin about how the firm is planning to be more active in making deals happen, as well as how it plans to address pressures on its Generics division that led to two consecutive downgrades in guidance this year.
Hikma Searches For New CEO As Olafsson Resigns
Hikma is looking for a new CEO after announcing that chief executive Siggi Olafsson will be leaving the company “to pursue other opportunities” on 24 June. In the meantime, executive chairman and former CEO Said Darwazah will take on his leadership responsibilities.